• Kite Pharma (KITE) Phase 1/2 Results of KTE-C19 for Pediatric ACute Lymphoblastic Leukemia

       (0 reviews)

    Biotech_Forecast
    Clinical and Regulatory
    Event Type: Phase 1/2 Results
    Timing: Q4 2016
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Oncology
    Indication: Pediatric Acute Lymphoblastic Leukemia
    Lead Indication?: Yes
    Treatment Name: KTE-C19

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Kite Pharma
    Stock Symbol: KITE
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=994338
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement

     

    Quote

     

    Kite is advancing its KTE-C19 pipeline with ongoing and expanded ZUMA studies to evaluate six additional indications:

    • ZUMA-2: Mantle cell lymphoma (MCL), with initial Phase 2 data expected in 2017
    • ZUMA-3: Adult acute lymphoblastic leukemia (Adult ALL), with initial Phase 1 data expected in 2016
    • ZUMA-4: Pediatric acute lymphoblastic leukemia (Pediatric ALL), with initial Phase 1 data expected in 2016
    • ZUMA-5: Indolent NHL, with first patient enrolled expected in the first quarter of 2017
    • ZUMA-7: 2nd line DLBCL, with first patient enrolled expected in 2017
    • ZUMA-8: Chronic lymphocytic leukemia (CLL), with first patient enrolled expected in 2017

     

     


      Report Event


    User Feedback

    There are no reviews to display.